---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011630"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:12:21.496008+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology

## Summary
- Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.
- He will oversee clinical and educational initiatives supporting the CBGM's intravascular placement approach.
- Glucotrack is advancing its CBGM through a long-term OUS early feasibility study and upcoming US pilot study.
- CBGM is a long-term implantable system measuring glucose directly from blood, with up to 3-year sensor life.

## SEC filing metadata
- accession: 0001493152-25-011630
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315225011630/0001493152-25-011630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315225011630/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011630
- JSON: https://secwatch.observer/filing/0001493152-25-011630.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.